Figure 4.

Decreased proteolysis and MMP expression upon disruption of GSK3β

(A–C) In situ gelatin degradation assay with either treatment of GSK3β SMI 1 μM (A) or siRNA (B) and quantification (C). n = 3.

(D and E) Analysis of mRNA expression of MMPs (D) 2 and (E) 9 indicate that their expression is decreased following SMI treatment; n = 3–4 independent experiments. 150 μm scale bars throughout.

(F and G) Gelatin zymography following 4 days treatment with DMSO, CHIRON, and AZ3 (F) alongside band quantification (G) for active MMP2, pro-MMP2, and pro-MMP9; n = 3 independent experiments.

In (C–E), comparisons were performed between MFS DMSO and drug treatment groups. Data are represented as mean ± SEM. Cells treated under control condition (DMSO) were also used as controls for Figure S3.